Author: Drew Senyei

Drew Senyei, Managing Director of Enterprise Partners since 1988, has over twenty years experience in the building of emerging, life science and healthcare companies. Enterprise Partners manages over $1.1 billion in capital, and has invested in more than 160 emerging growth companies since 1985. Enterprise Partners’ investors include major university endowments, corporate pension funds and institutional funds. Dr. Senyei has served on the Boards of over 25 private and public companies. In addition, Dr. Senyei serves on The Board of Trustees of Northwestern University and past chair of the UCSD Jacobs School of Engineering Advisory Council. He is the recipient of the 2007 E & Y San Diego Master Entrepreneur Award. Dr. Senyei is credited with thirty patents and over forty-five publications in peer-reviewed journals including: the New England Journal of Medicine and Proceedings of the National Academy of Science. He is the inventor of the first FDA-approved diagnostic test (Fetal Fibronectin) to predict premature birth, which has been used worldwide by over one million women at risk for preterm birth. He is the recipient of the 1998 Jonas Salk Mentor in Medicine Award from the March of Dimes and the University of California at Irvine distinguished Alumni Award. Drew was named one of the Top 100 VC’s in the US by Forbes magazine 2006 Midas Touch List. He is past president of San Diego Opera and currently serves as a board member. He is also a Tony award winner as one of the Producers of the hit Broadway musical “The Jersey Boys.” Dr. Senyei received his M.D. from Northwestern University and completed residency training in Obstetrics and Gynecology at the University of California, Irvine, where he served on the faculty prior to becoming active full time with venture capital funding of early stage medical companies.